Hikma gives US ‘skinny label’ generics stronger protection than in EU, practitioners say
By Nick Robertson ( October 30, 2026, 19:29 GMT | Comment) -- The US Supreme Court’s Hikma Pharmaceuticals v. Amarin Pharma decision this year makes induced patent infringement claims against “skinny label” generic drugmakers harder to plead, practitioners say, contrasting the ruling with European approaches that can give greater weight to prescribing practices and market conditions. The US Supreme Court’s ruling this summer on generic drug “skinny labels” has widened a divide with European approaches to infringement of pharmaceutical use patents, American and European practitioners say....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.